ProPhase Labs Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $8.47
- Today's High:
- $9.25
- Open Price:
- $9.12
- 52W Low:
- $6.6
- 52W High:
- $15.25
- Prev. Close:
- $9.15
- Volume:
- 147762
Company Statistics
- Market Cap.:
- $157.22 million
- Book Value:
- 3.557
- Revenue TTM:
- $94.42 million
- Operating Margin TTM:
- 8.82%
- Gross Profit TTM:
- $70.65 million
- Profit Margin:
- 6.9%
- Return on Assets TTM:
- 5.34%
- Return on Equity TTM:
- 10.32%
Company Profile
ProPhase Labs Inc had its IPO on 1997-01-16 under the ticker symbol PRPH.
The company operates in the Healthcare sector and Diagnostics & Research industry. ProPhase Labs Inc has a staff strength of 129 employees.
Stock update
Shares of ProPhase Labs Inc opened at $9.12 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $8.47 - $9.25, and closed at $8.58.
This is a -6.23% slip from the previous day's closing price.
A total volume of 147,762 shares were traded at the close of the day’s session.
In the last one week, shares of ProPhase Labs Inc have slipped by -7.74%.
ProPhase Labs Inc's Key Ratios
ProPhase Labs Inc has a market cap of $157.22 million, indicating a price to book ratio of 2.3894 and a price to sales ratio of 1.1351.
In the last 12-months ProPhase Labs Inc’s revenue was $94.42 million with a gross profit of $70.65 million and an EBITDA of $13.09 million. The EBITDA ratio measures ProPhase Labs Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ProPhase Labs Inc’s operating margin was 8.82% while its return on assets stood at 5.34% with a return of equity of 10.32%.
In Q1, ProPhase Labs Inc’s quarterly earnings growth was a negative -95.2% while revenue growth was a negative 59.4%.
ProPhase Labs Inc’s PE and PEG Ratio
- Forward PE
- 10.0908
- Trailing PE
- 23.4615
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.39 per share while it has a forward price to earnings multiple of 10.0908 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ProPhase Labs Inc’s profitability.
ProPhase Labs Inc stock is trading at a EV to sales ratio of 1.0169 and a EV to EBITDA ratio of 3.3778. Its price to sales ratio in the trailing 12-months stood at 1.1351.
ProPhase Labs Inc stock pays annual dividends of $0 per share, indicating a yield of 13.16% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $95.37 million
- Total Liabilities
- $18.47 million
- Operating Cash Flow
- $-1652000.00
- Capital Expenditure
- $517000
- Dividend Payout Ratio
- 0%
ProPhase Labs Inc ended 2023 with $95.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.37 million while shareholder equity stood at $59.94 million.
ProPhase Labs Inc ended 2023 with $0 in deferred long-term liabilities, $18.47 million in other current liabilities, 17000.00 in common stock, $12.30 million in retained earnings and $5.23 million in goodwill. Its cash balance stood at $9.61 million and cash and short-term investments were $15.56 million. The company’s total short-term debt was $298,000 while long-term debt stood at $9.62 million.
ProPhase Labs Inc’s total current assets stands at $61.28 million while long-term investments were $0 and short-term investments were $5.95 million. Its net receivables were $37.84 million compared to accounts payable of $4.87 million and inventory worth $4.31 million.
In 2023, ProPhase Labs Inc's operating cash flow was $-1652000.00 while its capital expenditure stood at $517000.
Comparatively, ProPhase Labs Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $8.58
- 52-Week High
- $15.25
- 52-Week Low
- $6.6
- Analyst Target Price
- $16.67
ProPhase Labs Inc stock is currently trading at $8.58 per share. It touched a 52-week high of $15.25 and a 52-week low of $15.25. Analysts tracking the stock have a 12-month average target price of $16.67.
Its 50-day moving average was $8.31 and 200-day moving average was $9.51 The short ratio stood at 4.11 indicating a short percent outstanding of 0%.
Around 2283.3% of the company’s stock are held by insiders while 1640.6% are held by institutions.
Frequently Asked Questions About ProPhase Labs Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.